💥 Gate Square Event: #PostToWinCGN 💥
Post original content on Gate Square related to CGN, Launchpool, or CandyDrop, and get a chance to share 1,333 CGN rewards!
📅 Event Period: Oct 24, 2025, 10:00 – Nov 4, 2025, 16:00 UTC
📌 Related Campaigns:
Launchpool 👉 https://www.gate.com/announcements/article/47771
CandyDrop 👉 https://www.gate.com/announcements/article/47763
📌 How to Participate:
1️⃣ Post original content related to CGN or one of the above campaigns (Launchpool / CandyDrop).
2️⃣ Content must be at least 80 words.
3️⃣ Add the hashtag #PostToWinCGN
4️⃣ Include a screenshot s
Innovent Biologics: Positive Results from Phase II Clinical Trial of Innovative Drug ICP-488
Jinshi data news on October 9th, Norcheng Jianhua announced in the evening that the company’s innovative drug ICP-488 achieved positive clinical trial results in a phase II randomized, double-blind, placebo-controlled study in patients with moderate to severe plaque psoriasis. The results showed that patients treated with 6mg and 9mg (once daily) of ICP-488 had significant improvement in PASI75 at week 12 compared to patients receiving placebo. In addition, the proportion of patients receiving ICP-488 treatment who achieved PASI90, PASI100, and static Physician Global Assessment (sPGA) 0/1 (i.e., complete or near-complete clearance of skin lesions) was significantly higher than that in the placebo group.